Major basic protein-1 promotes fibrosis of dystrophic muscle and attenuates the cellular immune response in muscular dystrophy.
The immune response to dystrophin-deficient muscle promotes the pathology of Duchenne muscular dystrophy (DMD) and the mdx mouse model of DMD. In this investigation, we find that the release of major basic protein (MBP) by eosinophils is a prominent feature of DMD and mdx dystrophy and that eosinophils lyse muscle cells in vitro by the release of MBP-1. We also show that eosinophil depletions of mdx mice by injections of anti-chemokine receptor-3 reduce muscle cell lysis, although lysis of mdx muscle membranes is not reduced by null mutation of MBP-1 in vivo. However, ablation of MBP-1 expression in mdx mice produces other effects on muscular dystrophy. First, fibrosis of muscle and hearts, a major cause of mortality in DMD, is greatly reduced by null mutation of MBP-1 in mdx mice. Furthermore, either ablation of MBP-1 or eosinophil depletion causes large increases in cytotoxic T-lymphocytes (CTLs) in mdx muscles. The increase in CTLs in MBP-1-null mice does not reflect a general shift toward a Th1 inflammatory response, because the mutation had no significant effect on the expression of interferon-gamma, inducible nitric oxide synthase or tumor necrosis factor. Rather, MBP-1 reduces the activation and proliferation of splenocytes in vitro, indicating that MBP-1 acts in a more specific immunomodulatory role to affect the inflammatory response in muscular dystrophy. Together, these findings show that eosinophil-derived MBP-1 plays a significant role in regulating muscular dystrophy by attenuating the cellular immune response and promoting tissue fibrosis that can eventually contribute to increased mortality.
Wehling-Henricks
Michelle
M
Department of Physiological Science, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA90095-1606, USA.
Sokolow
Sophie
S
Lee
Jamie J
JJ
Myung
Kyu H
KH
Villalta
S Armando
SA
Tidball
James G
JG
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D003964:Diaphragm / Q000276:immunology / Q000473:pathology; D004195:Disease Models, Animal; D047093:Eosinophil Major Basic Protein / Q000235:genetics / Q000502:physiology*; D004804:Eosinophils / Q000276:immunology*; D005355:Fibrosis; D006801:Humans; D047589:Leukocyte Reduction Procedures; D051379:Mice; D018101:Mice, Inbred mdx; D018482:Muscle, Skeletal / Q000276:immunology / Q000473:pathology; D009132:Muscles / Q000276:immunology / Q000473:pathology*; D020388:Muscular Dystrophy, Duchenne / Q000235:genetics / Q000276:immunology* / Q000473:pathology*; D009154:Mutation; D009206:Myocardium / Q000276:immunology / Q000473:pathology; D054397:Receptors, CCR3 / Q000037:antagonists & inhibitors; D012038:Regeneration / Q000235:genetics; D013154:Spleen / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D000911:Antibodies, Monoclonal; D054397:Receptors, CCR3; D047093:Eosinophil Major Basic Protein